16 January 2020 - Arena Pharmaceuticals today announced that the U.S. FDA granted fast track designation for APD418, a β3-adrenergic receptor antagonist and cardiac myotrope, in development for the treatment of decompensated heart failure.
APD418 is a first-in-class β3-adrenergic receptor antagonist and cardiac myotrope for decompensated heart failure. APD418 is a selective antagonist designed to improve cardiac contractility with minimal effect on heart rate, blood pressure and myocardial oxygen consumption, thus potentially avoiding adverse events associated with current inotrope therapies.